Rhode Island
Requires Coverage of Comprehensive Biomarker Testing
Yes
Highlighted Disparity
No racial disparities were found in Rhode Island for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Rhode Island is 59.1 and significantly higher than the national rate of 52.8.
- It ranks 37th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases in Rhode Island improved by 15%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Rhode Island is 37.6%, which is significantly higher than the national rate of 29.7%.
- It ranks 1st among the 39 states with survival data, placing it in the top tier.
- Over the last five years, the survival rate in Rhode Island improved by 32%.
Early Diagnosis:
- In Rhode Island, 35.5% of cases are caught at an early stage, which is significantly higher than the national rate of 28.1%.
- It ranks 1st among the 50 states with data on diagnosis at an early stage, placing it in the top tier.
- Over the last five years, the early diagnosis rate in Rhode Island improved by 33%.
Lung Cancer Treatment
Biomarker Coverage:
- Rhode Island was one of the 17 states that required insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Rhode Island ranked 4th (out of the 49 states with available data) with 24.5% of cases undergoing surgery as part of the first course of treatment.
- This is significantly higher than the national rate of 20.7% and puts Rhode Island in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in Rhode Island did not change significantly.
No Treatment:
- Rhode Island ranked 2nd (out of the 49 states with available data) with 13.3% of cases not receiving any treatment.
- This is significantly lower than the national rate of 21.0% and puts Rhode Island in the top tier.
- Over the last five years, the percent of cases receiving no treatment in Rhode Island did not change significantly.
Screening
Screening for High Risk:
- In Rhode Island, 31.0% of those at high risk were screened, which was significantly higher than the national rate of 18.2%.
- It ranks 1st among all states, placing it in the top tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in Rhode Island is 9.5% and significantly lower than the national rate of 11.4%.
- It ranks 9th among all states, placing it in the above average tier.
Radon Exposure:
- In Rhode Island, 21.4% of radon test results were at or above the action level recommended by EPA.
- It ranks 22nd among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 52.3 per 100,000 population among Black individuals in Rhode Island, not significantly different than the rate of 54.2 among Black individuals nationally, and not significantly different than the rate of 62.0 among white individuals in Rhode Island.
- The five-year survival rate is 45.1% among Black individuals in Rhode Island, significantly higher than the rate of 27.1% among Black individuals nationally, and not significantly different than the rate of 36.8% among white individuals in Rhode Island.
- 39.6% of lung cancer cases are diagnosed at an early stage among Black individuals in Rhode Island, significantly higher than the rate of 25.1% among Black individuals nationally, and not significantly different than the rate of 35.7% among white individuals in Rhode Island.
- 22.5% of Black individuals with lung cancer in Rhode Island underwent surgery, not significantly different than the rate of 17.1% among Black individuals nationally, and not significantly different than the rate of 24.9% among white individuals in Rhode Island.
- Other lung cancer rates are not available for Black individuals in Rhode Island due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- The rate of new lung cancer cases is 27.1 per 100,000 population among Latino individuals in Rhode Island, not significantly different than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 62.0 among white individuals in Rhode Island.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 31.7% of lung cancer cases are diagnosed at an early stage among Latino individuals in Rhode Island, not significantly different than the rate of 23.9% among Latino individuals nationally, and not significantly different than the rate of 35.7% among white individuals in Rhode Island.
- 19.7% of Latino individuals with lung cancer in Rhode Island underwent surgery, not significantly different than the rate of 21.4% among Latino individuals nationally, and not significantly different than the rate of 24.9% among white individuals in Rhode Island.
- 18.3% of Latino individuals with lung cancer in Rhode Island did not receive any treatment, significantly lower than the rate of 25.8% among Latino individuals nationally, and not significantly different than the rate of 13.0% among white individuals in Rhode Island.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 36.1 per 100,000 population among Asian or Pacific Islanders individuals in Rhode Island, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 62.0 among white individuals in Rhode Island.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Asian or Pacific Islander individuals in Rhode Island due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Rhode Island due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Rhode Island falling into the top tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Rhode Island was one of the states that required insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Rhode Island falls into the top tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
